Results 11 to 20 of about 645 (124)

Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. [PDF]

PLoS ONE, 2014
Sutezolid (PNU-100480) is a linezolid analog with superior bactericidal activity against Mycobacterium tuberculosis in the hollow fiber, whole blood and mouse models.
Robert S Wallis, Rodney Dawson, Sven O Friedrich, Amour Venter, Darcy Paige, Tong Zhu, Annette Silvia, Jason Gobey, Craig Ellery, Yao Zhang, Kathleen Eisenach, Paul Miller, Andreas H Diacon   +12 more
doaj   +10 more sources

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB. [PDF]

J Antimicrob Chemother
Funding: This study was conducted by the PanACEA consortium, funded by the EDCTP2 programme (grant number TRIA2015-1102) with support from the German Ministry for Education and Research (BMBF; 01KA1701); further funding was contributed by the German ...
Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, Wallis R, Ntinginya NE, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Zumba T, Noreña I, Peter DD, Beattie T, Makkan H, Sloan DJ, Te Brake L, Aarnoutse RE, McHugh TD, Wildner L, Schildkraut J, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N, PanACEA consortium .   +28 more
europepmc   +10 more sources

Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China [PDF]

International Journal of Infectious Diseases, 2021
Background: The natural resistance of rapidly growing mycobacteria (RGM) to multiple antibiotics renders the treatment of the infections caused less successful.
Shu’an Wen, Xiaopan Gao, Weijie Zhao, Fengmin Huo, Guanglu Jiang, Lingling Dong, Liping Zhao, Fen Wang, Xia Yu, Hairong Huang   +9 more
doaj   +3 more sources

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. [PDF]

PLoS ONE, 2012
There presently is no rapid method to assess the bactericidal activity of new regimens for tuberculosis. This study examined PNU-100480, TMC207, PA-824, SQ109, and pyrazinamide, singly and in various combinations, against intracellular M.
Robert S Wallis, Wesley Jakubiec, Mark Mitton-Fry, Lynn Ladutko, Sheldon Campbell, Darcy Paige, Annette Silvia, Paul F Miller   +7 more
doaj   +4 more sources

To be or not to be exclusive: the sutezolid story [PDF]

The Lancet Global Health, 2016
Response from Johns Hopkins University Johns Hopkins University is deeply committed to providing access to essential medicines, and has been working for years to advance the goal of ensuring that promising therapies for tuberculosis reach the market in an expeditious and accessible way.
Christy Wyskiel
doaj   +6 more sources

Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects. [PDF]

Antimicrob Agents Chemother, 2022
The primary objective of the study was to evaluate the safety and tolerability of single oral doses of sutezolid tablets administered under fasting conditions in healthy adult subjects. The secondary objective was to determine the pharmacokinetics (PK) of sutezolid and two metabolites, PNU-101603 and PNU-101244.
Bruinenberg P, Nedelman J, Yang TJ, Pappas F, Everitt D.   +4 more
europepmc   +3 more sources

In Vitro Efficacy Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Rapid Growing Mycobacteria Isolated in Beijing, China [PDF]

, 2021
Abstract The natural resistance of rapid growth Mycobacterium (RGM) against multiple antibiotics renders the treatment of caused infections less successful and time consuming. Therefore, new effective agents are urgently needed. The aim of this study was to evaluate the in vitro susceptibility of 115 isolates, constituting different RGM species,
Shuan Wen, Xiaopan Gao, Weijie Zhao, Fengmin Huo, Guanglu Jiang, Lingling Dong, Liping Zhao, Fen Wang, Xia Yu, Hairong Huang   +9 more
openaire   +2 more sources

Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures. [PDF]

J Antimicrob Chemother
Abstract Background New and shorter regimens against multi-drug resistant tuberculosis (TB) remain urgently needed. To inform treatment duration in clinical trials, this study aimed to identify human pharmacokinetic equivalent doses, antimycobacterial and sterilizing activity of a novel regimen ...
Walter K, Te Brake LHM, Lemm AK, Hoelscher M, Svensson EM, Hölscher C, Heinrich N.   +6 more
europepmc   +7 more sources

Mycobacterium tuberculosis: Pathogenesis and therapeutic targets

MedComm, Volume 4, Issue 5, October 2023., 2023
In this review, we summarize the pathogenesis of TB infection, therapeutic targets, and corresponding modulators, including first‐line medications, current clinical trial drugs and molecules in preclinical assessment. Our review provides valuable insights for future antituberculosis drug development efforts.
Jiaxing Yang, Laiying Zhang, Wenliang Qiao, Youfu Luo   +3 more
wiley   +1 more source

Advances in Key Drug Target Identification and New Drug Development for Tuberculosis

BioMed Research International, Volume 2022, Issue 1, 2022., 2022
Tuberculosis (TB) is a severe infectious disease worldwide. The increasing emergence of drug‐resistant Mycobacterium tuberculosis (Mtb) has markedly hampered TB control. Therefore, there is an urgent need to develop new anti‐TB drugs to treat drug‐resistant TB and shorten the standard therapy.
Jie Mi, Wenping Gong, Xueqiong Wu, Atef M. Al Attar   +3 more
wiley   +1 more source